This WHO and HRP guideline is designed to help countries make faster progress, more equitably, on the screening and treatment of cervical cancer. This document includes guidance on an important additional option for cervical screening, the use of mRNA (messenger RNA) HPV testing. This gives countries additional options when considering which type of HPV nucleic acid amplification tests (NAAT) to use in their screening programs. In this present publication, only recommendations for the use of HPV mRNA testing are presented. For other recommendations, please refer to the July 2021 publication of the WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition.